{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:39:08Z","timestamp":1780475948580,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bcmd.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T19:10:12Z","timestamp":1457205012000},"page":"37-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Gregory M.","family":"Pastores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadhami Ben","family":"Turkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derlis E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza A.G.","family":"Tantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.03.004_bb0005","series-title":"The Metabolic & Molecular Bases of Inherited Diseases","first-page":"3635","article-title":"Gaucher Disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.bcmd.2016.03.004_bb0010","series-title":"CEREZYME\u00ae (Imiglucerase for Injection)","author":"Genzyme Corporation","year":"2005"},{"key":"10.1016\/j.bcmd.2016.03.004_bb0015","unstructured":"Shire Human Genetic Therapies, Inc., VPRIV\u00ae (velaglucerase alfa for injection): highlights of prescribing information, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022575s012lbl.pdf (Accessed on October 4, 2015)."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0020","unstructured":"Pfizer Inc., ELEYSO\u2122 (taliglucerase alfa) for injection: highlights of prescribing information, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022458s003s006lbl.pdf (Accessed on October 4, 2015)."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0025","unstructured":"European Medicines Agency, Cerezyme: EPAR\u2014product information, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000157\/WC500024112.pdf (Accessed on October 4, 2015)."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0035","article-title":"A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: results after a cumulative treatment period of 24months","author":"Ida","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0040","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","article-title":"Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience","volume":"115","author":"Zimran","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2016.03.004_bb0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ajh.24040","article-title":"Seven-year safety and efficacy with velaglucerase alfa for treatment-na\u00efve adult patients with type 1 Gaucher disease","volume":"90","author":"Zimran","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0055","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0060","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.23383","article-title":"Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase","volume":"88","author":"Zimran","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ajh.24007","article-title":"Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease","volume":"90","author":"Elstein","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/gim.2013.154","article-title":"A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability","volume":"16","author":"Pastores","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0080","first-page":"131","article-title":"Examination of the efficacy and safety of enzyme replacement therapy with velaglucerase alfa in Japanese Gaucher disease patients","volume":"78","author":"Ida","year":"2015","journal-title":"Asian J. Pediatr. Pract."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2015.12.456","article-title":"Velaglucerase alfa enzyme replacement therapy in children and adolescents with type 3 Gaucher disease: results of a 12-month multicenter, open-label phase 1\/2 study","author":"Tantawy","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.bcmd.2016.03.004_bb0095","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20130081","article-title":"Glycosylation and functionality of recombinant beta-glucocerebrosidase from various production systems","volume":"33","author":"Tekoah","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0105","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12257-012-0095-1","article-title":"Current status and perspectives of biopharmaceutical drugs","volume":"17","author":"Ryu","year":"2012","journal-title":"Biotechnol. Bioprocess Eng."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0115","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nbt1303","article-title":"A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs","volume":"25","author":"Shankar","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0120","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation","volume":"149","author":"Jawa","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0130","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0135","unstructured":"Shire, efficacy and safety study of velaglucerase alfa in children and adolescents with type 3 Gaucher disease, http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT01685216 (Accessed on Nov 12, 2015)."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0140","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jim.2011.07.020","article-title":"Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease","volume":"373","author":"S\u00e9llos-Moura","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcmd.2016.03.004_bb0145","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ymgme.2014.12.185","article-title":"An inter-laboratory comparison study of detection and characterization of anti-velaglucerase alfa antibodies","volume":"114","author":"Najarian","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cca.2007.02.042","article-title":"Monitoring of Gaucher patients with a novel chitotriosidase assay","volume":"381","author":"Schoonhoven","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcmd.2016.03.004_bb0155","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.nmd.2014.06.255","article-title":"Effects of antibody formation during enzyme replacement therapy in 73 adult patients with Pompe disease","volume":"24","author":"de Vries","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bcmd.2016.03.004_bb0160","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616300171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:31:37Z","timestamp":1761049897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616300171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":32,"alternative-id":["S1079979616300171"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.03.004","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors and Shire. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}